Clinical Trial Update: Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD [Phase 3]

View source ↗

Summary

Clinical trial update for revefenacin Phase 3 assessing peak inspiratory flow rate in COPD; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Snippet

Sponsor: Mylan Inc. | Conditions: Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR) | Phase 3 | Status: COMPLETED | Results posted: 2018-12-31